DE602004017622D1 - Matrixmetalloproteinaseinhibitoren - Google Patents

Matrixmetalloproteinaseinhibitoren

Info

Publication number
DE602004017622D1
DE602004017622D1 DE602004017622T DE602004017622T DE602004017622D1 DE 602004017622 D1 DE602004017622 D1 DE 602004017622D1 DE 602004017622 T DE602004017622 T DE 602004017622T DE 602004017622 T DE602004017622 T DE 602004017622T DE 602004017622 D1 DE602004017622 D1 DE 602004017622D1
Authority
DE
Germany
Prior art keywords
alkyl
alkylaryl
cor
optionally substituted
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004017622T
Other languages
English (en)
Inventor
Simon Gaines
Ian Peter Holmes
Stephen Lewis Martin
Stephen Paul Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602004017622D1 publication Critical patent/DE602004017622D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
DE602004017622T 2003-09-13 2004-09-10 Matrixmetalloproteinaseinhibitoren Active DE602004017622D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds
PCT/EP2004/010319 WO2005026120A1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
DE602004017622D1 true DE602004017622D1 (de) 2008-12-18

Family

ID=29227079

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004031991T Active DE602004031991D1 (de) 2003-09-13 2004-09-10 Matrix-Metalloproteinaseinhibitoren
DE602004017622T Active DE602004017622D1 (de) 2003-09-13 2004-09-10 Matrixmetalloproteinaseinhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602004031991T Active DE602004031991D1 (de) 2003-09-13 2004-09-10 Matrix-Metalloproteinaseinhibitoren

Country Status (29)

Country Link
US (3) US7601729B2 (de)
EP (3) EP2295408A1 (de)
JP (3) JP2007505081A (de)
KR (3) KR20060120648A (de)
CN (1) CN1849306B (de)
AT (2) ATE413384T1 (de)
AU (1) AU2004272280C1 (de)
BR (1) BRPI0413791A (de)
CA (1) CA2538315C (de)
CY (1) CY1109400T1 (de)
DE (2) DE602004031991D1 (de)
DK (1) DK1663970T3 (de)
ES (2) ES2314436T3 (de)
GB (1) GB0321538D0 (de)
HK (1) HK1092141A1 (de)
HR (1) HRP20080668T3 (de)
IL (1) IL173305A (de)
IS (2) IS2622B (de)
MA (1) MA28039A1 (de)
MX (1) MXPA06002458A (de)
NO (1) NO20060540L (de)
NZ (2) NZ573479A (de)
PL (1) PL1663970T3 (de)
PT (1) PT1663970E (de)
RU (2) RU2370488C2 (de)
SG (1) SG145685A1 (de)
SI (1) SI1663970T1 (de)
WO (1) WO2005026120A1 (de)
ZA (1) ZA200602070B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
ES2381681T3 (es) * 2005-02-22 2012-05-30 Ranbaxy Laboratories Limited Derivados de ácido 5-fenil-pentanoico como inhibidores de la metaloproteinasa matriz para el tratamiento del asma y otras enfermedades
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
CN101528691B (zh) * 2006-08-22 2014-11-26 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
AU2011284397A1 (en) 2010-07-30 2013-02-21 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
US20140148459A1 (en) 2010-09-24 2014-05-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
US20160045463A1 (en) 2012-11-28 2016-02-18 Universidad De Salamanca Use of metalloprotease inhibitors in the treatment of polycystic liver diseases
MD3413892T2 (ro) 2016-02-12 2022-06-30 Cytokinetics Inc Derivați de tetrahidroizochinolină
CN110769866B (zh) * 2017-06-13 2022-07-29 爱惜康有限责任公司 具有可控愈合的外科缝合器

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU2199195A (en) * 1994-04-28 1995-11-29 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
TR199801000T2 (xx) * 1995-12-06 1998-08-21 Astra Pharmaceuticals Ltd. Bile�ikler
AU725847B2 (en) 1996-04-19 2000-10-19 Merck Sharp & Dohme B.V. Substituted benzylamines and their use for the treatment of depression
CO4990925A1 (es) * 1996-05-15 2000-12-26 Bayer Corp Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
US5789605A (en) * 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6096904A (en) * 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6870058B2 (en) * 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US20050065353A1 (en) * 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US6242616B1 (en) * 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2490819A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2004012663A2 (en) 2002-08-01 2004-02-12 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
BR0314898A (pt) * 2002-11-19 2005-08-02 Galderma Res & Dev Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
GB0312654D0 (en) * 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
ES2381681T3 (es) * 2005-02-22 2012-05-30 Ranbaxy Laboratories Limited Derivados de ácido 5-fenil-pentanoico como inhibidores de la metaloproteinasa matriz para el tratamiento del asma y otras enfermedades
CN101528691B (zh) * 2006-08-22 2014-11-26 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂

Also Published As

Publication number Publication date
JP2011231118A (ja) 2011-11-17
CA2538315A1 (en) 2005-03-24
KR20060120648A (ko) 2006-11-27
IL173305A (en) 2011-01-31
RU2006106850A (ru) 2007-10-20
CA2538315C (en) 2014-04-08
IS8268A (is) 2006-01-26
CN1849306A (zh) 2006-10-18
PL1663970T3 (pl) 2009-04-30
CN1849306B (zh) 2014-01-29
US8263602B2 (en) 2012-09-11
US7601729B2 (en) 2009-10-13
EP1663970A1 (de) 2006-06-07
ES2314436T3 (es) 2009-03-16
PT1663970E (pt) 2009-01-09
RU2370488C2 (ru) 2009-10-20
HK1092141A1 (en) 2007-02-02
BRPI0413791A (pt) 2006-11-07
US20100029699A1 (en) 2010-02-04
IS8843A (is) 2009-08-19
AU2004272280C1 (en) 2011-10-27
DE602004031991D1 (de) 2011-05-05
ATE413384T1 (de) 2008-11-15
EP2042488B1 (de) 2011-03-23
US20090082377A1 (en) 2009-03-26
KR20120007566A (ko) 2012-01-20
NZ573479A (en) 2010-09-30
US20060293353A1 (en) 2006-12-28
SI1663970T1 (sl) 2009-04-30
NO20060540L (no) 2006-04-04
JP2012107031A (ja) 2012-06-07
SG145685A1 (en) 2008-09-29
AU2004272280A1 (en) 2005-03-24
HRP20080668T3 (en) 2009-02-28
US8343986B2 (en) 2013-01-01
MA28039A1 (fr) 2006-07-03
ES2362954T3 (es) 2011-07-15
ZA200602070B (en) 2007-05-30
IL173305A0 (en) 2006-06-11
KR20130079628A (ko) 2013-07-10
CY1109400T1 (el) 2014-07-02
GB0321538D0 (en) 2003-10-15
DK1663970T3 (da) 2009-01-12
MXPA06002458A (es) 2006-06-20
ATE502922T1 (de) 2011-04-15
IS2622B (is) 2010-05-15
EP2042488A1 (de) 2009-04-01
JP2007505081A (ja) 2007-03-08
RU2008146479A (ru) 2010-06-20
WO2005026120A1 (en) 2005-03-24
NZ545211A (en) 2009-01-31
AU2004272280B2 (en) 2011-04-21
EP1663970B1 (de) 2008-11-05
EP2295408A1 (de) 2011-03-16

Similar Documents

Publication Publication Date Title
HRP20080668T3 (en) Matrix metalloproteinase inhibitors
ATE362910T1 (de) Matrix metalloprotease inhibitoren
BR0201697A (pt) Compostos de alfa-aminoácid0, processo para a sua preparação e composições farmacêuticas contendo os mesmos
SE8008680L (sv) Basiska etrar, sett for deras framstellning och farmaceutiska beredningar innehallande dem
HUP0201475A2 (hu) Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
BG106847A (en) Substituted piperazine derivatives as mtp inhibitors
DK1010698T3 (da) Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem
ATE239021T1 (de) Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EA200301079A1 (ru) Терапевтическое средство по поводу повышенной чувствительности мочевого пузыря
DK1188752T3 (da) Fremgangsmåde til fremstilling af substitueret alkylaminderivat
WO2005016868A3 (en) Matrix metalloproteinase inhibitors
BR0101466A (pt) Compostos de ciclobutaindolcarboxamida,processo para a sua preparação e composiçõesfarmacêuticas contendo os mesmos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition